SGX Pharmaceuticals Q1 cash: $35.8mln, up from $17.7mln, includes $20.6mln IPO, $5mln Novartis payment.

• SGX Pharmaceuticals reports Q1 2006 financial results • Cash and cash equivalents at $35.8 million, up from $17.7 million in December 2005 • $20.6 million from IPO and $5 million from Novartis deal included in the balance • SGX Pharmaceuticals announces a license and collaboration agreement with Novartis Institutes for Biomedical Research • The agreement includes a $25 million upfront payment, with $20 million remaining to be received.